Back to News
Market Impact: 0.3
Monte Rosa's MRT-6160 Enters Phase 2 Trial For Moderate To Severe Psoriatic Arthritis; Stock Up
Source: Nasdaq
Healthcare & Biotech
Novartis initiated a second Phase 2 clinical study of Monte Rosa Therapeutics’ investigational VAV1-directed molecular glue degrader MRT-6160 (DDY391). The study will enroll participants with active moderate to severe psoriatic arthritis.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
GLUE0.55
NVS0.15
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Dassault Systèmes raises 2026 outlook as revenue growth rebound gathers pace
- Needham initiates Clover Health stock with buy on cohort economics